Test Price
650 AED✅ Home Collection Available
Cultured AFB Anti‑Tubercular Drug Susceptibility Testing (DST) for Ofloxacin in UAE
Executive Summary & Core Metrics
Test Purpose
Determines phenotypic susceptibility of Mycobacterium tuberculosis to ofloxacin, directly guiding multidrug-resistant TB (MDR-TB) regimen selection.
Price
650 AED (includes automated broth-based DST processing and specialist clinical interpretation).
Methodology
Automated Fluorescent Broth-Based DST (BACTEC™ MGIT™ 960) – ISO 9001:2015 certified workflow.
Logistical Protocol
Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
Test Overview & Methodology
The Cultured AFB Drug Susceptibility Test for Ofloxacin evaluates a pure isolate of Mycobacterium tuberculosis to determine sensitivity or resistance to the fluoroquinolone ofloxacin. This phenotypic result is essential for constructing effective MDR‑TB and pre‑XDR‑TB treatment regimens. The assay employs the fully automated BACTEC™ MGIT™ 960 system, which continuously monitors fluorescence to detect microbial growth in the presence of a standardized concentration of ofloxacin, delivering objectively measured susceptibility endpoints within a defined incubation window.
| Feature | DNA Labs UAE Procedure | Conventional Alternative |
|---|---|---|
| Precision / Method | Automated Fluorescent Broth-Based DST (BACTEC™ MGIT™ 960) | Proportion Method on solid Löwenstein‑Jensen medium |
| Turnaround Time | 21 days from pure culture receipt | 28–42 days |
| Clinical Utility | Directly guides MDR‑TB / pre‑XDR‑TB regimen choice and improves treatment outcomes | Same utility but prone to contamination delays and manual variability |
Physician Insight & Safety Protocols
“As a specialist overseeing TB diagnostics, I emphasize that phenotypic ofloxacin susceptibility testing must be interpreted alongside molecular line probe assay results and the full clinical history. A susceptible result supports the inclusion of ofloxacin in contemporary shortened MDR‑TB regimens, while resistance demands immediate transition to alternative second‑line agents to prevent treatment failure and further resistance amplification.” – Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology (DHA Registration ID: 61713011)
Medication Advisory
Do not discontinue or alter your prescribed anti‑tuberculosis medication without consulting your treating physician. Abrupt changes can lead to drug resistance, treatment failure, and disease relapse.
Exclusion Criteria & Safety Red Flags
- Specimen Restriction: This test accepts only pure culture isolates of Mycobacterium tuberculosis. Direct sputum or blood samples are not processed for DST.
- Growth Requirement: Inadequate or contaminated bacterial growth may necessitate a repeat culture and delay results.
- Emergency Signs: Seek immediate medical care if you experience worsening cough with hemoptysis, high fever unresponsive to antipyretics, severe chest pain, or confusion while undergoing TB treatment.
- Professional Interpretation Required: This test is not intended for self‑interpretation; all results must be reviewed by a licensed infectious disease or pulmonology specialist.
Patient FAQ & Clinical Guidance
1. What does the Cultured AFB DST Ofloxacin test detect?
A: It determines whether Mycobacterium tuberculosis bacteria grown from your culture are susceptible or resistant to the antibiotic ofloxacin, providing critical data for precisely tailoring your MDR‑TB therapy.
2. Why must I submit a pure culture rather than a direct sputum sample?
A: Drug susceptibility testing requires a pure, viable bacterial isolate to accurately measure drug response without interference from normal respiratory flora or non‑viable organisms.
3. How soon should I consult my doctor after receiving my results?
A: Schedule an appointment as soon as you receive the report. Any evidence of resistance requires rapid clinical decision‑making to adjust your regimen and prevent treatment failure.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): All patient health information and test results are processed under strict data protection protocols ensuring confidentiality and lawful processing.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: Digital health records and tele‑clinical guidance are delivered through secure, auditable ICT infrastructure compliant with national health information governance standards.
- Federal Decree-Law No. 4 of 2016 on Medical Liability: Clinical safety, patient consent, and professional accountability are strictly enforced across every phase of specimen handling and diagnostic reporting.
- ISO 9001:2015 Certified (Certification No. INT/EGQ/2509DA/3139).
- DHA Facility License: 1143.
Clinical & Logistical Metadata
| Test Name | Cultured AFB Anti‑Tubercular Drug Susceptibility Testing (DST) for Ofloxacin |
| Price (AED) | 650 |
| Turnaround Time | 21 days from pure culture receipt |
| Sample Type / Matrix | Pure Culture Isolate (Mycobacterium tuberculosis) |
| Methodology Used | Automated Fluorescent Broth-Based DST (BACTEC™ MGIT™ 960) |
| ICD-10-CM Code | Z11.1 |
| LOINC Code | 68545-1 |
| DHA Facility License & Laboratory Address | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE (License: 1143) |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians